



200D1y1yt@N6CNSJ5

CRH MEDICAL CORPORAT
CRH FORM 8-K

Donnelley Financial
None

VDI-W7-PFL-2623
14.4.10.0

ADG thanj0dc
VAN

22-Dec-2020 12:56 EST

101264 TX 1 4*
XHT ESS 0C

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Rule 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
December 22, 2020

CRH MEDICAL CORPORATION

(Exact name of registrant as specified in its charter)

British Columbia, Canada
(State or other jurisdiction
of incorporation)

001-37542
(Commission
File Number)

Not Applicable
(IRS Employer
Identification No.)

Suite 578 – 999 Canada Place, World Trade Center, Vancouver,
British Columbia, Canada
(Address of principal executive offices)

V6C 3E1
(Zip Code)

(604) 633-1440
(Registrant's telephone number, including area code)

Not Applicable
(Former name of former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



ITEM 7.01 REGULATION FD DISCLOSURE

On December 22, 2020 CRH Medical Corporation issued a press release commenting on the COVID-19 relief bill passed yesterday by the United States Congress. A copy of the press release is being furnished herewith as Exhibit 99.1.

The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release issued by CRH Medical Corporation on December 22, 2020
104	Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL)



200D!y1yt@KcjlNBjJ

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CRH MEDICAL CORPORATION

(Registrant)

Date: December 22, 2020

By: /s/ Richard Bear

Name: Richard Bear

Title: Chief Financial Officer



CRH Medical Corporation Comments on Recently Passed Billing Legislation

VANCOUVER, BC, Dec. 22, 2020 /CNW/ - **CRH Medical Corporation** ("**CRH**", or the "**Company**") (TSX: CRH) (NYSE MKT: CRHM) today commented on the COVID-19 relief bill passed yesterday by the United States Congress.

Lawmakers included the long-awaited surprise billing legislation into the relief bill. The surprise billing legislation has three important components that are scheduled to go into effect in 2022:

- The legislation allows for a 30-day period whereby the insurer and provider can negotiate payment for any out-of-network claims.
- If these negotiations are not successful, then the next step would be third-party arbitration.
- In the event of arbitration, an arbitrator is not required to consider a geographic benchmark payment level, and is prohibited from factoring in Medicare and Medicaid rates when determining out-of-network payment.

"We expect the provider-friendly language of the recently passed surprise billing legislation will serve to meaningfully advance our contracting negotiations with payors in a manner that will more fairly reflect the value of the services we provide to our patients," noted Dr. Tushar Ramani, Chief Executive Officer of CRH. "As a reminder, our payor contracting effort is a key part of our larger strategy to minimize our non-contracted revenue exposure, which we view as positively impacting future revenue and profit visibility."

About CRH Medical Corporation:

CRH Medical Corporation is a North American company focused on providing gastroenterologists throughout the United States with innovative services and products for the treatment of gastrointestinal diseases. In 2014, CRH became a full-service gastroenterology anesthesia company that provides anesthesia



2000!y1yt@J-M5kw

CRH MEDICAL CORPORAT
CRH FORM 8-K

Donnelley Financial

VDI-W7-PFL-1960
14.4.1

ADG ARUMK0TV

22-Dec-2020 10:47 EST

101264 EX99 1 1 1*

VAN

HTE BIU OC

services for patients undergoing endoscopic procedures in ambulatory surgical centers. To date, CRH has completed 31 anesthesia acquisitions, and now serves 68 ambulatory surgical centers in 13 states. In addition, CRH owns the CRH O'Regan System, a single-use, disposable, hemorrhoid banding technology that is safe and highly effective in treating all grades of hemorrhoids. CRH distributes the O'Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to gastroenterology practices, creating meaningful relationships with the gastroenterologists it serves. CRH's O'Regan System is currently used in all 48 lower US states.

View original content:<http://www.prnewswire.com/news-releases/crh-medical-corporation-comments-on-recently-passed-billing-legislation-301197592.html>

SOURCE CRH Medical Corporation

View original content:

<http://www.newswire.ca/en/releases/archive/December2020/22/c7691.html>

%CIK: 0001461119

For further information: Constantine Davides, CFA, 339-970-2846, constantine.davides@westwicke.com, <http://investors.crhsystem.com/>

CO: CRH Medical Corporation

CNW 10:02e 22-DEC-20